Cargando…

Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies

BACKGROUND: Tumor-stroma ratio (TSR) has been suggested as an emerging prognostic predictor in women with breast cancer. However, previous studies evaluating the association between TSR and survival in women with breast cancer showed inconsistent results. We performed a meta-analysis to systematical...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Pengli, Chen, Yulong, Liu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716503/
https://www.ncbi.nlm.nih.gov/pubmed/34976792
http://dx.doi.org/10.3389/fonc.2021.731409
_version_ 1784624336107208704
author Jiang, Pengli
Chen, Yulong
Liu, Bin
author_facet Jiang, Pengli
Chen, Yulong
Liu, Bin
author_sort Jiang, Pengli
collection PubMed
description BACKGROUND: Tumor-stroma ratio (TSR) has been suggested as an emerging prognostic predictor in women with breast cancer. However, previous studies evaluating the association between TSR and survival in women with breast cancer showed inconsistent results. We performed a meta-analysis to systematically evaluate the possible prognostic role of TSR in breast cancer. METHODS: Relevant cohort studies were obtained via search of PubMed, Embase, and Web of Science databases. A random-effects model, which incorporated the potential heterogeneity, was used to pool the results. RESULTS: Twelve cohort studies with 6175 patients were included. Nine of the 12 studies used 50% as the cutoff to divide the patients into those with stroma-rich (low TSR) and stroma-poor (high TSR) tumors. Pooled results showed that compared women with stroma-poor tumor, those with stroma-rich tumor were associated with worse survival outcomes (disease-free survival [DFS]: hazard ratio [HR] = 1.56, 95% confidence interval [CI]: 1.32 to 1.85, P < 0.001; overall survival [OS]: HR = 1.67, 95% CI: 1.46 to 1.91, P < 0.001; and cancer-specific survival [CSS]: HR = 1.75, 95% CI: 1.40 to 2.20, P < 0.001). Analysis limited to women with triple-negative breast cancer (TNBC) showed consistent results (DFS: HR: 2.07, 95% CI: 1.59 to 2.71, P < 0.001; OS: HR: 2.04, 95% CI: 1.52 to 2.73, P < 0.001; and CSS: HR: 2.40, 95% CI: 1.52 to 3.78, P < 0.001). CONCLUSIONS: Current evidence from retrospective studies supports that tumor TSR is a prognostic predictor or poor survival in women with breast cancer.
format Online
Article
Text
id pubmed-8716503
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87165032021-12-31 Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies Jiang, Pengli Chen, Yulong Liu, Bin Front Oncol Oncology BACKGROUND: Tumor-stroma ratio (TSR) has been suggested as an emerging prognostic predictor in women with breast cancer. However, previous studies evaluating the association between TSR and survival in women with breast cancer showed inconsistent results. We performed a meta-analysis to systematically evaluate the possible prognostic role of TSR in breast cancer. METHODS: Relevant cohort studies were obtained via search of PubMed, Embase, and Web of Science databases. A random-effects model, which incorporated the potential heterogeneity, was used to pool the results. RESULTS: Twelve cohort studies with 6175 patients were included. Nine of the 12 studies used 50% as the cutoff to divide the patients into those with stroma-rich (low TSR) and stroma-poor (high TSR) tumors. Pooled results showed that compared women with stroma-poor tumor, those with stroma-rich tumor were associated with worse survival outcomes (disease-free survival [DFS]: hazard ratio [HR] = 1.56, 95% confidence interval [CI]: 1.32 to 1.85, P < 0.001; overall survival [OS]: HR = 1.67, 95% CI: 1.46 to 1.91, P < 0.001; and cancer-specific survival [CSS]: HR = 1.75, 95% CI: 1.40 to 2.20, P < 0.001). Analysis limited to women with triple-negative breast cancer (TNBC) showed consistent results (DFS: HR: 2.07, 95% CI: 1.59 to 2.71, P < 0.001; OS: HR: 2.04, 95% CI: 1.52 to 2.73, P < 0.001; and CSS: HR: 2.40, 95% CI: 1.52 to 3.78, P < 0.001). CONCLUSIONS: Current evidence from retrospective studies supports that tumor TSR is a prognostic predictor or poor survival in women with breast cancer. Frontiers Media S.A. 2021-12-16 /pmc/articles/PMC8716503/ /pubmed/34976792 http://dx.doi.org/10.3389/fonc.2021.731409 Text en Copyright © 2021 Jiang, Chen and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Jiang, Pengli
Chen, Yulong
Liu, Bin
Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies
title Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies
title_full Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies
title_fullStr Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies
title_full_unstemmed Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies
title_short Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies
title_sort prognostic efficacy of tumor-stroma ratio in women with breast cancer: a meta-analysis of cohort studies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716503/
https://www.ncbi.nlm.nih.gov/pubmed/34976792
http://dx.doi.org/10.3389/fonc.2021.731409
work_keys_str_mv AT jiangpengli prognosticefficacyoftumorstromaratioinwomenwithbreastcancerametaanalysisofcohortstudies
AT chenyulong prognosticefficacyoftumorstromaratioinwomenwithbreastcancerametaanalysisofcohortstudies
AT liubin prognosticefficacyoftumorstromaratioinwomenwithbreastcancerametaanalysisofcohortstudies